We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Recently, Ronapreve, a product of Roche Pharmaceuticals, was approved by the Japanese Ministry of Health, Labour and Welfare for the treatment of mild to moderate COVID-19 patients by intravenous infusion.
The CDE issued five documents including the Technical Guidelines for the Research and Development of Prophylactic Vaccines against COVID-19 (Trial) on Aug. 14.